The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Basic Information
ID: ALA4152198
Journal: Eur J Med Chem
Title: The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Authors: Liang C, Tian D, Ren X, Ding S, Jia M, Xin M, Thareja S.
Abstract: Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly haematopoietic malignancies and autoimmune diseases related to B lymphocytes. This review focuses on the diverse, small-molecule inhibitors of BTK kinase that have shown good prospects for clinical application. Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed. Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK. The present review also surveys the pharmacological advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire critical thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.
CiteXplore: 29631132
DOI: 10.1016/j.ejmech.2018.03.062
Patent ID: ┄